Skip to main content

Table 1 Patient baseline demographics and clinical characteristics

From: Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India

Demographic/characteristic

All enrolled patients

(N = 250)

Age, y, mean (SD)

60.2 (9.4)

Male, n (%)

169 (67.6)

Type 2 diabetes,a n (%)

188 (75.2)

≥1 Relevant ophthalmic condition,b n (%)

91 (36.4)

 Time since diagnosis, y, mean (SD)

1.7 (2.6)

 Treated eye,c n

91

  Right only, n (%)

17 (18.7)

  Left only, n (%)

13 (14.3)

  Both, n (%)

61 (67.0)

Prior medications for DME, n

 DEX

84

 Dexamethasone (systemic)

6

 Bevacizumab

5

 Ranibizumab

4

 Treated eye, n

84

  Right only, n (%)

35 (41.7)

  Left only, n (%)

45 (53.6)

  Both, n (%)

4 (4.8)

Concomitant medications for diabetes, n (%)

 Metformin

114 (45.6)

 Glimepiride

76 (30.4)

Concomitant medications for cardiovascular conditions, n (%)

 Telmisartan

55 (22.0)

 Atorvastatin

32 (12.8)

 Blood and blood-forming agents

44 (17.6)

Last prior DEX dose to study entry dose, d

n

80

 Mean (SD)

199.4 (156.0)

 Min, max

0, 891

  1. DEX dexamethasone intravitreal implant; DME diabetic macular edema; SD standard deviation
  2. aType was not specified in 60 (24%) patients; b“Relevant ophthalmic conditions” in medical history includes all ophthalmic conditions; cFive patients reported condition as “not treated” despite all patients reporting one (right/left) or both eyes being treated